Peptide Romania
healing

TB-500

Thymosin Beta-4 fragment

Studied in tissue regeneration and actin-binding cellular repair pathways.

Dovezi
Preliminary
T½
~2 h
Categorie
healing
Status
Investigational

Evaluarea dovezilor

Baza de dovezi

Preliminary16%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Studied in tissue regeneration and actin-binding cellular repair pathways.

T½~2 h
StatusInvestigational
Categoriehealing
DoveziPreliminary

Întrebări frecvente

Ce trebuie să știi

Studied in tissue regeneration and actin-binding cellular repair pathways.
TB-500 has Preliminary evidence. Very limited data exists, primarily anecdotal reports or single exploratory studies without independent replication in peer-reviewed literature yet.
The half-life of TB-500 is ~2 h. This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
TB-500 is currently classified as: Investigational. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Studied in tissue regeneration and actin-binding cellular repair pathways.
Înapoi la peptide